Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 5/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2845082 | 0.93 | CYP1A2 (0.56) | HTR7CYP1A2MAPK1SMN1; SMN2PAOX | |
| SCHEMBL2843063 | 0.92 | CYP1A2 (0.54) | HTR7CYP1A2MAPK1SMN1; SMN2PAOX | |
| SCHEMBL659239 | 0.86 | CYP1A2 (0.52) | HTR7CYP1A2MAPK1SMN1; SMN2PAOX | |
| SCHEMBL26180910 | 0.86 | CYP1A2 (0.68) | HTR7CYP1A2MAPK1SMN1; SMN2PAOX | |
| SCHEMBL8380184 | 0.86 | CYP1A2 (0.68) | HTR7CYP1A2MAPK1SMN1; SMN2PAOX | |
| SCHEMBL8381328 | 0.84 | CYP1A2 (0.65) | CYP1A2MAPK1SMN1; SMN2PAOXTDP1 | |
| SCHEMBL4910508 | 0.82 | PAOX (0.69) | HTR7CYP1A2MAPK1SMN1; SMN2PAOX | |
| SCHEMBL24694352 | 0.82 | CYP1A2 (0.52) | HTR7CYP1A2MAPK1SMN1; SMN2PAOX | |
| Sebacic Acid SCHEMBL4458306 | 0.82 | CYP1A2 (0.63) | CYP1A2MAPK1SMN1; SMN2PAOXTDP1 | |
| SCHEMBL4914342 | 0.81 | GNAI3 (0.50) | HTR7CYP1A2PAOXPIK3CDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104098526-A | Amidophenyl-1,3,4-oxadiazole compound and its preparation method and use | UNIV EAST CHINA NORMAL | 2014-10-15 | — | — | CN | disclosed |
| US-20080275028-A1 | Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof | SIENA BIOTECH S.P.A. (IT) | 2008-11-06 | — | — | US | disclosed |
| CN-101018774-A | Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof | SIENA BIOTECH SPA (IT) | 2007-08-15 | — | — | CN | disclosed |
| EP-1778658-A2 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | Siena Biotech S.p.A. (IT) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006008133-A2 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | SIENA BIOTECH S.P.A. (IT) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275028-A1 | Modulators or Alpha7 Nicotinic Acetylcholine Receptors and Therapeutic Uses Thereof | CHRNA7, CHRNA5, CHRNA1 | HTR7 24/4885CYP1A2 1878/4885MAPK1 1753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.